AXON enters the post-earnings week in a curious spot: the stock fell nearly 14% on its August 5 print, then clawed back more than 12% over the following month, closing Tuesday at $636.31 — above where it traded before the report.
The short interest story has shifted materially since the pre-earnings note published on August 5. Bears held roughly 4.9% of the float short going into the print; they now hold 4.8%, and the direction has reversed sharply. Short interest dropped 5.4% in a single session on August 11 and is down about 10% over the past month. That's a meaningful retreat — shorts that built positions ahead of earnings appear to have covered into the weakness, not added. The borrow market confirms there's no renewed pressure: availability runs at 506%, meaning roughly five shares remain available for every one currently lent out, and the cost to borrow is a negligible 0.49%. The lending pool is as loose as it's been all year.
Options tell a slightly more cautious story, though the divergence is mild. The put/call ratio is running at 1.05, about 1.7 standard deviations above its 20-day average — modestly elevated relative to the calm pre-earnings regime when it sat near 1.00. That's not alarm-level defensiveness, but it does mark a shift. Traders seem to be hedging the recovery rather than chasing it outright, which is a reasonable posture given the stock has essentially round-tripped the earnings selloff in less than two weeks.
The Street moved quickly after the print. Morgan Stanley raised its target to $640 from $600 while keeping Overweight, and Barclays lifted aggressively — from $523 to $688 — also maintaining Overweight. Piper Sandler nudged its target to $732, and UBS bumped to $600 from $440 while staying Neutral. The direction of travel is unmistakably bullish: most firms raised targets the day after what was ostensibly a disappointing earnings reaction, implying the underlying numbers were better than the price move suggested. The consensus mean target of $662 sits roughly 4% above the current price — tight, but not stretched given the pace of target upgrades. Bulls point to Axon's expanding platform ecosystem, body-camera and cloud software recurring revenues, and the Dedrone counter-UAS business. The one visible bear position — UBS at Neutral with a $600 target — remains below where the stock is already trading, which makes it a soft headwind at best.
CEO and founder Patrick Smith sold shares on August 7 across multiple transactions totaling approximately $2.5 million at prices between $535 and $565. The trades carry low significance scores and appear consistent with a scheduled plan rather than a directional view — particularly notable given the stock has since run well past those sale prices. Institutional holders are broadly supportive: BlackRock reported adding 345,000 shares as of July 31, and Baillie Gifford added roughly 600,000 shares through June. Wellington Management added 878,000 shares in the same period. The ownership picture looks constructive rather than crowded.
The next earnings event is scheduled for November 3. Between now and then, the key question is whether the stock can hold and extend past analyst targets as they continue to reprice upward, or whether the put/call nudge higher signals that investors view $636 as pricing in a lot of the good news already.
See the live data behind this article on ORTEX.
Open AXON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
